NEW YORK, Jan. 27, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq:XBIT) between April 15, 2015 and November 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Texas. If you purchased or otherwise acquired XBiotech securities between April 15, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 



